<DOC>
	<DOCNO>NCT00179686</DOCNO>
	<brief_summary>Subjects qualify receive single agent lenalidomide daily day 1-21 28 day cycle . Subjects continue disease progression document .</brief_summary>
	<brief_title>A Study Evaluate Single-Agent Lenalidomide Subjects With Recurrent Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form . 2 . Age &gt; = 18 year time signing informed consent form 3 . Able adhere study visit schedule protocol requirement 4 . Must histologically confirm diagnosis non small cell lung cancer recur follow least two prior regimen . Those regimen must contain platinum compound taxane either sequentially combination 5 . Subjects must measurable disease cross sectional imaging least 2 cm long diameter . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 ( see Appendix II ) . 7 . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day start study drug . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study drug . WCBP must agree pregnancy test every 4 week study drug ( every 14 day woman irregular cycle ) 4 week last dose study drug . 1 . Any following laboratory abnormality : 1 . Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) 2 . Platelet count &lt; 100,000/mm3 ( 100 x 109/L ) 3 . Serum creatinine &gt; 2.5 mg/dL ( 221 mmol/L ) 4 . Serum SGOT/AST SGPT/ALT &gt; 5.0 x upper limit normal ( ULN ) 5 . Serum total bilirubin &gt; 2.0 mg/dL ( 34 mmol/L ) 2 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 3 . Prior history malignancy nonsmall cell lung cancer ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease &gt; = 1 year . 4 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 5 . Pregnant lactating female . 6 . Prior &gt; = grade 3 allergic reaction/hypersensitivity thalidomide . 7 . Prior &gt; = grade 3 rash desquamating ( blister ) rash take thalidomide . 8 . Prior use lenalidomide . 9 . Use standard/experimental anticancer drug therapy within 28 day initiation study drug therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>celgene</keyword>
	<keyword>cc-5013</keyword>
	<keyword>NSCLC</keyword>
	<keyword>CC5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>